Market Cap 198.04M
Revenue (ttm) 0.00
Net Income (ttm) -156.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.74
Volume 736,531
Avg Vol 988,768
Day's Range N/A - N/A
Shares Out 58.59M
Stochastic %K 31%
Beta 2.20
Analysts Sell
Price Target $22.50

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
Wallywwu
Wallywwu Jun. 26 at 5:51 PM
$OMER where’s the coiled spring? Was told this would explode?!?! Market up big, but not this hmmmmm
1 · Reply
LeaLeb
LeaLeb Jun. 26 at 5:21 PM
$OMER Notice to shorts, if tomorrow Greg says anything specific about current conversations with partners this thing could really fly.
2 · Reply
vu_jade
vu_jade Jun. 26 at 4:43 PM
$OMER idiots
0 · Reply
investlong871
investlong871 Jun. 26 at 3:34 PM
$OMER it feels like a big gamble for Greg to be at these levels without a solid backup plan. Approval seems likely, sure, but the rest of the pipeline is too valuable to have no backup plan for funding the company. EU submission AND partner would be lovely right now IMO.
1 · Reply
LeaLeb
LeaLeb Jun. 26 at 3:22 PM
$OMER Maybe tomorrow our nightmare comes to an end, it will all depend how confident Greg is gonna be and how detailed he'll get into company financials.. otherwise we continue like this price suppression until FDA decision.
1 · Reply
MinnieSteve3
MinnieSteve3 Jun. 26 at 2:27 PM
$OMER Less than 3 months until September 25 and yet someone continues to hammer this stock downward. Looking forward to hearing from Greg tomorrow.
1 · Reply
stiffy1
stiffy1 Jun. 26 at 6:31 AM
$OMER SI up again to just over 13m
2 · Reply
TheNewAxe
TheNewAxe Jun. 25 at 8:37 PM
$OMER Have been holding on for a two handle, but gave up today and added 10k at 3.56. Let’s see what happens! 🤷😎
0 · Reply
Jbaffs
Jbaffs Jun. 25 at 6:12 PM
$OMER Up 6% on little to no volume. Imagine when the party starts!!!!!
3 · Reply
ipdamages
ipdamages Jun. 25 at 4:03 PM
$OMER Bucking XBI/LABU drop with at least moderate volume today. Nice to see. Two years ago during the ASM Greg said that they had finally made headway with FDA on a path forward to resubmit the BLA by comparing to a historical data set, which he expected would result in approval. I added significantly within a couple minutes of him saying that, during the call. Let’s see what he has to say in two days about goings on with the company.
2 · Reply
Latest News on OMER
Omeros Corporation Reports First Quarter 2025 Financial Results

May 15, 2025, 4:05 PM EDT - 6 weeks ago

Omeros Corporation Reports First Quarter 2025 Financial Results


Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 11, 2025, 3:06 PM EDT - 2 months ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight


Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 8:57 PM EDT - 3 months ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript


Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:22 PM EST - 8 months ago

Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript


Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:02 PM EST - 8 months ago

Omeros Corporation Reports Third Quarter 2024 Financial Results


Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:05 AM EDT - 11 months ago

Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript


Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:02 PM EDT - 11 months ago

Omeros Corporation Reports Second Quarter 2024 Financial Results


Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:23 PM EDT - 1 year ago

Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript


Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 8:09 PM EDT - 1 year ago

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript


Omeros: Why It Is Worthwhile To Bet On Narsoplimab

Nov 27, 2023, 1:18 AM EST - 1 year ago

Omeros: Why It Is Worthwhile To Bet On Narsoplimab


Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript

Nov 10, 2023, 10:32 AM EST - 1 year ago

Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript


Wallywwu
Wallywwu Jun. 26 at 5:51 PM
$OMER where’s the coiled spring? Was told this would explode?!?! Market up big, but not this hmmmmm
1 · Reply
LeaLeb
LeaLeb Jun. 26 at 5:21 PM
$OMER Notice to shorts, if tomorrow Greg says anything specific about current conversations with partners this thing could really fly.
2 · Reply
vu_jade
vu_jade Jun. 26 at 4:43 PM
$OMER idiots
0 · Reply
investlong871
investlong871 Jun. 26 at 3:34 PM
$OMER it feels like a big gamble for Greg to be at these levels without a solid backup plan. Approval seems likely, sure, but the rest of the pipeline is too valuable to have no backup plan for funding the company. EU submission AND partner would be lovely right now IMO.
1 · Reply
LeaLeb
LeaLeb Jun. 26 at 3:22 PM
$OMER Maybe tomorrow our nightmare comes to an end, it will all depend how confident Greg is gonna be and how detailed he'll get into company financials.. otherwise we continue like this price suppression until FDA decision.
1 · Reply
MinnieSteve3
MinnieSteve3 Jun. 26 at 2:27 PM
$OMER Less than 3 months until September 25 and yet someone continues to hammer this stock downward. Looking forward to hearing from Greg tomorrow.
1 · Reply
stiffy1
stiffy1 Jun. 26 at 6:31 AM
$OMER SI up again to just over 13m
2 · Reply
TheNewAxe
TheNewAxe Jun. 25 at 8:37 PM
$OMER Have been holding on for a two handle, but gave up today and added 10k at 3.56. Let’s see what happens! 🤷😎
0 · Reply
Jbaffs
Jbaffs Jun. 25 at 6:12 PM
$OMER Up 6% on little to no volume. Imagine when the party starts!!!!!
3 · Reply
ipdamages
ipdamages Jun. 25 at 4:03 PM
$OMER Bucking XBI/LABU drop with at least moderate volume today. Nice to see. Two years ago during the ASM Greg said that they had finally made headway with FDA on a path forward to resubmit the BLA by comparing to a historical data set, which he expected would result in approval. I added significantly within a couple minutes of him saying that, during the call. Let’s see what he has to say in two days about goings on with the company.
2 · Reply
MinnieSteve3
MinnieSteve3 Jun. 25 at 1:41 PM
$OMER 3 months from today (or sooner) -- September 25
0 · Reply
SteadyasSheGoes
SteadyasSheGoes Jun. 25 at 3:39 AM
$OMER My expectations for Friday; 1) Narso EU MAA submission as promised. 2) Update on the financials, including cash on hand, ATM use and savings from paused programs. What else?
3 · Reply
Rjsmall
Rjsmall Jun. 24 at 8:28 PM
1 · Reply
OmerNeedsCFO
OmerNeedsCFO Jun. 24 at 8:26 PM
$OMER what is the LABU? We had 619k shares traded at 3:00. We traded 700k shares in last hour for little to no price change…?
1 · Reply
gordonator
gordonator Jun. 24 at 7:59 PM
$OMER good volume I think the good doc got some good cash
1 · Reply
Stocksfirst
Stocksfirst Jun. 24 at 7:40 PM
$OMER - looks like Mike Logan has gone underground???
1 · Reply
vu_jade
vu_jade Jun. 24 at 7:36 PM
$OMER double bottom bounce .. Lets go
0 · Reply
naturegirl669
naturegirl669 Jun. 24 at 7:10 PM
$OMER - FUNNY!!!!!........NXTR Doubles After Promising Eczema Drug Trial Results..........Eczema.....REALLY!!!!! But we probably have the best drugs for cidney, compulsion and cancer......ONE DAY, VERY SOON!!!!
0 · Reply
Jbaffs
Jbaffs Jun. 24 at 6:06 PM
$OMER my apologies to the board. Next time I'll verify before posting.
1 · Reply
izacmann
izacmann Jun. 24 at 4:48 PM
$OMER we only have good news. We just don’t have cash. Yet. Let’s get that figured out GD.
1 · Reply
Jbaffs
Jbaffs Jun. 24 at 4:29 PM
$OMER doesn't Q3 start one week from today? Conclusion The next readout for OMS906 is expected in Q3 2025 from Phase 2 trials in PNH (switch-over) and C3G, with further data presentation at ASH in December 2025. These milestones could drive significant stock upside and enhance $OMER’s M&A potential, complementing narsoplimab and OMS527 catalysts. Monitor Omeros’ investor updates for confirmation.
2 · Reply
Jbaffs
Jbaffs Jun. 24 at 4:13 PM
From GROK - Conclusion If narsoplimab is approved for TA-TMA in September 2025, there is a strong possibility (60–70% likelihood) of label expansion to other diseases, particularly aHUS or IgAN, by 2027–2028, driven by shared complement-mediated mechanisms, ongoing Phase 3 trials, and regulatory support (Breakthrough, Orphan designations). AHUS is the most likely due to its TMA similarity, with IgAN following if Phase 3 proteinuria data holds. Lupus nephritis is less certain (30–40%) due to longer timelines and competition. Expansion would boost $OMER’s valuation ($500M$1B), M&A appeal (70–80%), and OMS527 funding, making it a compelling buy $OMER
2 · Reply